Second Genome, Inc. is a biopharmaceutical company - formerly dba as PhyloTech Inc - focused on microbiome drug discovery and development. The firm's mission is described as to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery and ahs has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partnersâ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases with the lead candidate being SGM-1019 - a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in inflammatory bowel disease (IBD). The company is also involved in various preclinical programs under development for a range of chronic indications. Second Genome, Inc. has strategic partnerships with Janssen Biotech, with Pfizer and with the Mayo Clinic
